| __timestamp | Cytokinetics, Incorporated | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17268000 | 17986000 |
| Thursday, January 1, 2015 | 19667000 | 32480000 |
| Friday, January 1, 2016 | 27823000 | 68081000 |
| Sunday, January 1, 2017 | 36468000 | 169906000 |
| Monday, January 1, 2018 | 31282000 | 248932000 |
| Tuesday, January 1, 2019 | 39610000 | 354100000 |
| Wednesday, January 1, 2020 | 52820000 | 433300000 |
| Friday, January 1, 2021 | 96803000 | 583300000 |
| Saturday, January 1, 2022 | 177977000 | 752700000 |
| Sunday, January 1, 2023 | 173612000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, managing operational expenses is crucial for sustained growth. Over the past decade, Neurocrine Biosciences, Inc. and Cytokinetics, Incorporated have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Neurocrine's SG&A expenses surged by nearly 500%, peaking in 2023, reflecting their aggressive expansion and investment in administrative capabilities. In contrast, Cytokinetics exhibited a more conservative growth of approximately 900%, with a notable spike in 2022. This divergence highlights Neurocrine's robust financial strategy, potentially positioning them for greater market penetration. Meanwhile, Cytokinetics' steady approach may indicate a focus on sustainable growth. As these companies navigate the complexities of the biotech sector, their SG&A efficiency will be pivotal in determining their future trajectories.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Novartis AG and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Incyte Corporation Trends and Insights
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Celldex Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Cytokinetics, Incorporated or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and ImmunityBio, Inc.
Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and BioCryst Pharmaceuticals, Inc.